Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1168P - Survey of challenges in access to diagnostics and treatment for neuroendocrine tumour (NET) patients (SCAN): Healthcare quality evaluation


17 Sep 2020


E-Poster Display


Tumour Site

Neuroendocrine Neoplasms


Catherine Bouvier


Annals of Oncology (2020) 31 (suppl_4): S711-S724. 10.1016/annonc/annonc281


C.V. Bouvier1, D. Van Genechten2, T. Kolarova3, M. McDonnell4, D. O'Toole5, H. Singh6, J. Chen7, J. Howe8, S. Singh9, C. Rodien-Louw10, S. Leyden11, S. Dureja12

Author affiliations

  • 1 Co-founder And Ceo, Neuroendocrine Cancer UK, CV32 4JL - Royal Leamington Spa/GB
  • 2 Vice-president, vzw NET & MEN Kanker Belgium, Kortrijk/BE
  • 3 Executive Director, International Neuroendocrine Cancer Alliance (INCA), 1000 - Sofia/BG
  • 4 Chair, NET Patient Network, Dublin/IE
  • 5 Gastroenterology, St Vincents University Hospital, D04 T6F4 - Dublin/IE
  • 6 Surgery, Prince Court Medical Centre 39, Kuala Lumpur/MY
  • 7 Gastroenterology, The First Affiliated Hospital, Sun Yat-Sen University, Guangdong/CN
  • 8 Surgical Oncology And Endocrine Surgery, University of Iowa, 52242 - Iowa City/US
  • 9 Medical Oncology, Sunnybrook Odette Cancer Center, Sunnybrook HSC, M4N 3M5 - Toronto/CA
  • 10 President, APTED, Lyon/FR
  • 11 President, NeuroEndocrine Cancer Australia, Blairgowrie/AU
  • 12 Nuclear Medicine And Molecular Imaging Department, Fortis Memorial Research Institute, 122002 - Gurugram/IN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1168P


Neuroendocrine tumors (NETs) are rare and complex neoplasms with increasing incidence and prevalence worldwide. SCAN assessed global delivery of NET healthcare.


During Sept-Nov 2019, NET patients and healthcare professionals (HCPs) completed an online survey, available in 14 languages, which was disseminated via social media and NET patient group networks.


There were 2795 respondents from 68 countries composed of 436 HCPs (of which medical oncologists (MO) comprised 25% [103/436]); 2359 NET patients/carers. The regions included: Europe (47%); North America (NA) (31%); Asia (12%); Oceania (9%]; South America & Africa (2%). Almost half (46% [1077/2359]) of patients had stage IV NETs. Mean time to diagnosis was 5 years and 1042 were misdiagnosed, lower in Asia and higher in NA (All: Europe 4.05 vs. NA 6.44 vs. Asia 2.28 vs. Oceania 4.81 (T-test, p<0.0001). The quality of healthcare provided was evaluated by NET patients at 3.5 (5-points Likert scale) (All: Europe 3.61 vs. NA 3.61 vs. Asia 2.56, vs. Oceania 3.83) and by HCPs/MOs at 3.3/3.1 [All: 436, MO: 102]. Slightly over half of NET patients were consulted by a NET specialist in past 12 months (P12M), notably from Europe and Oceania (All: 53% [1273/2359]; Europe: 61% [672/1102], NA: 48% [348/727], Asia: 42% [118/280], Oceania: 53% [106/200], p<0.0001, Chi-squared). Only one third of patient cases were reviewed by a multidisciplinary team in P12M, less in NA and Asia (All: 33% [779/2359]; Europe: 38% [419/1102], NA: 29% [217/727], Asia: 22% [62/280], Oceania: 39% [70/200], p<0.0001. A MO was the most involved HCP in the follow-up in 60% of NET patients, particularly in NA and Oceania (All: Europe 54% [593/1102] vs. NA 75% [548/727] vs. Asia 34% [95/280], vs. Oceania 75% [150/200] p<0.0001). The most common recommendation to improve NET diagnosis and management, given by MO, was ‘better access to NET experts/specialist centers (71% [77/103]).


The delivery of healthcare to NET patients is in need of significant improvement globally to ensure proper and timely diagnosis and treatment. Improving access to multidisciplinary care should be a priority for healthcare systems when it comes to NETs.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

International Neuroendocrine Cancer Alliance.


Ipsen, ITM, Novartis.


J. Chen: Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Ipsen. S. Singh: Research grant/Funding (institution): Novartis; Honoraria (self): Ipsen; Honoraria (self): Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.